Fluocinolone acetonide
Fluocinolone acetonide
|
|
Systematic (IUPAC) name |
---|
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
Clinical data |
---|
AHFS/Drugs.com |
International Drug Names |
---|
|
|
---|
|
|
---|
|
Topical |
---|
Pharmacokinetic data |
---|
Metabolism |
Hepatic, CYP3A4-mediated |
---|
Half-life |
1.3 to 1.7 hours |
---|
Identifiers |
---|
|
67-73-2 Y |
---|
|
C05AA10 D07AC04 S01BA15 S02BA08 |
---|
PubChem |
CID 6215 |
---|
DrugBank |
DB00591 Y |
---|
ChemSpider |
5980 Y |
---|
UNII |
0CD5FD6S2M Y |
---|
KEGG |
D01825 Y |
---|
ChEBI |
CHEBI:31623 N |
---|
ChEMBL |
CHEMBL989 Y |
---|
Chemical data |
---|
Formula |
C24H30F2O6 |
---|
|
452.488 g/mol |
---|
SMILES
- O=C\1\C=C5/[C@@](/C=C/1)(C)[C@]2(F)[C@H]([C@H]3[C@](C[C@@H]2O)([C@@]4(OC(O[C@@H]4C3)(C)C)C(=O)CO)C)C[C@@H]5F
|
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
Y
Key:FEBLZLNTKCEFIT-VSXGLTOVSA-N
Y
|
N (what is this?) (verify) |
---|
Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching. It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.[1] Preparations containing it were first marketed under the name Synalar. A typical dosage strength used in dermatology is 0.01–0.025%. One such cream is sold under the brand name Flucort-N and includes the antibiotic neomycin.
Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.[2]
Flucinolone is a group IV (0.01-0.2%) or group V (0.025%) corticosteroid under US classification.
See also
References
- ↑ J S Mills, A. Bowers, Carl Djerassi and H.J. Ringold, Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide, Journal of the American Chemical Society, 80, 3399-3404 (1960)
- ↑ Hara ES, Ono M, Hai PT, Sonoyama W, Kubota S, Takigawa M, Matsumoto T, Young MF, Olsen BR, Kuboki T. Fluocinolone Acetonide is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration. J Bone Miner Res. 2015. http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2502/abstract
|
---|
| Agonists | |
---|
| Antagonists / SGRMs | |
---|
| Synthesis modifiers | |
---|
|
| | |
---|
| Description |
- Glands
- Hormones
- thyroid
- mineralocorticoids
- Physiology
- Development
|
---|
| Disease |
- Diabetes
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
|
---|
| Treatment |
- Procedures
- Drugs
- calcium balance
- corticosteroids
- oral hypoglycemics
- pituitary and hypothalamic
- thyroid
|
---|
|
|
|
---|
| Antihemorrhoidals for topical use | |
---|
| Antivaricose therapy | |
---|
| Capillary stabilising agents | |
---|
| |
---|
| Description |
- Anatomy
- Arteries
- head and neck
- arms
- chest
- abdomen
- legs
- Veins
- head and neck
- arms
- chest
- abdomen and pelvis
- legs
- Development
- Cells
- Physiology
|
---|
| Disease |
- Congenital
- Neoplasms and cancer
- Lymphatic vessels
- Injury
- Vasculitis
- Other
- Symptoms and signs
|
---|
| Treatment |
- Procedures
- Drugs
- beta blockers
- channel blockers
- diuretics
- nonsympatholytic vasodilatory antihypertensives
- peripheral vasodilators
- renin–angiotensin system
- sympatholytic antihypertensives
- vasoprotectives
|
---|
|
|
|
---|
| Receptor | |
---|
| Enzyme | |
---|
| Others | |
---|
| See also: Androgenics • Estrogenics • Mineralocorticoidics • Progestogenics |
|